Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Cysteine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.41 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.41 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.35 |
| ▸ | MMP2 | P08253 | 2/20 | 0.34 |
| ▸ | MMP9 | P14780 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 4/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | GRM8 | O00222 | 1/20 | 0.33 |
| ▸ | GRM6 | O15303 | 1/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.33 |
| ▸ | GSR | P00390 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cysteine SCHEMBL4587284 | 0.95 | KMT2A (0.46) | KMT2AALOX15BLMPMP22PTGS1 | |
| SCHEMBL4292884 | 0.83 | KMT2A (0.44) | KMT2AALOX15BLMPMP22FOLH1 | |
| Glutamine SCHEMBL6931889 | 0.79 | ALOX15 (0.68) | KMT2AALOX15BLMPMP22PTGS1 | |
| Glutamine SCHEMBL3513355 | 0.79 | ALOX15 (0.68) | KMT2AALOX15BLMPMP22PTGS1 | |
| SCHEMBL3651670 | 0.74 | FOLH1 (0.53) | FOLH1MMP9 | |
| SCHEMBL21802287 | 0.74 | KMT2A (0.47) | KMT2AALOX15BLMPMP22FOLH1 | |
| SCHEMBL6554061 | 0.74 | KMT2A (0.47) | KMT2AALOX15BLMPMP22FOLH1 | |
| Glutamine SCHEMBL2129419 | 0.72 | ALOX15 (0.79) | KMT2AALOX15BLMPMP22PTGS1 | |
| Glutamine SCHEMBL285915 | 0.72 | ALOX15 (0.79) | KMT2AALOX15BLMPMP22PTGS1 | |
| Glutamine SCHEMBL285916 | 0.72 | ALOX15 (0.79) | KMT2AALOX15BLMPMP22PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293702-A1 | Nitric Oxide Enhancing Pyruvate Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080287407-A1 | Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| EP-1692107-A4 | NITRIC OXIDE RELEASING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2008-10-29 | — | — | EP | disclosed |
| EP-1971340-A2 | NITRIC OXIDE ENHANCING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2008-09-24 | — | — | EP | disclosed |
| WO-2007075542-A2 | NITRIC OXIDE ENHANCING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| EP-1692107-A2 | NITRIC OXIDE RELEASING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005060603-A2 | NITRIC OXIDE RELEASING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293702-A1 | Nitric Oxide Enhancing Pyruvate Compounds, Compositions and Methods of Use | PC, PDK1, NOS3 | KMT2A 3491/4885ALOX15 966/4885BLM 3719/4885 |
| US-20080287407-A1 | Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use | PC, PDK1, NOS3 | KMT2A 3995/4885ALOX15 640/4885BLM 4131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.